On the stock market since 2023, it operates in the world of health and science. It has 13 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 32% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $2.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 1 buy and 0 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $5.00 — 873% above today’s price.
A loss of $3.7M against $2.0M in annual sales.
The stock sits at $0.51. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, AIDX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AIDX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (14/100) says the stock isn’t cheap.